---
title: "NEWAMSTERDAM PHARMA COMPANY — Ownership Dossier"
canonical: https://whiteintel.dev/entity/3fa46f7d-2bb8-5de2-b41c-e151a6263d7e
json: https://whiteintel.dev/api/public/dossier/3fa46f7d-2bb8-5de2-b41c-e151a6263d7e
identifier: cusip:N62509117
jurisdiction: US
source: WhiteIntel corporate-ownership graph
---

# NEWAMSTERDAM PHARMA COMPANY

**Type:** Asset  
**Jurisdiction:** [US](https://whiteintel.dev/jurisdictions/us)  
**Identifier:** `cusip:N62509117`  
**Canonical dossier:** https://whiteintel.dev/entity/3fa46f7d-2bb8-5de2-b41c-e151a6263d7e  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/3fa46f7d-2bb8-5de2-b41c-e151a6263d7e  

## Ownership & control

### UBO chain (walk to the ultimate owner)

A **21-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Provenance

- SEC 13F — https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **NEWAMSTERDAM PHARMA COMPANY**. Human view: https://whiteintel.dev/entity/3fa46f7d-2bb8-5de2-b41c-e151a6263d7e · Structured JSON: https://whiteintel.dev/api/public/dossier/3fa46f7d-2bb8-5de2-b41c-e151a6263d7e._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._